GMAB vs HCA: fair value comparison
Genmab A/S and HCA Healthcare, Inc. · Updated 2026-09-06
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, GMAB currently sits closer to the top of our discount ranking. GMAB carries the stronger quality grade.
| GMAB | HCA | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $28.68 | $405.00 |
| 12-month range | $25.45–$33.27 | $370.96–$532.92 |
| Sector rank | #48 of 113 Healthcare | #52 of 113 Healthcare |
| Quality grade | A | C |
| Leverage | Low | Low |
| Margin trend | Contracting | Stable |
| Revenue growth | Declining | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | — |
| DCF cross-check | Undervalued | Overvalued |
| 52-week position | The lower-middle quarter | The bottom quarter |
Full single-stock breakdowns: GMAB fair value analysis · HCA fair value analysis